Quantitative Correlation of in Vivo Properties with in Vitro Assay Results: The in Vitro Binding of a Biotin-DNA Analogue Modifier with Streptavidin Predicts the in Vivo Avidin-Induced Clearability of the Analogue-Modified Antibody.

Quantitative prediction of in vivo behavior using an in vitro assay would dramatically accelerate pharmaceutical development. However, studies quantitatively correlating in vivo properties with in vitro assay results are rare because of the difficulty in quantitatively understanding the in vivo behavior of an agent. We now demonstrate such a correlation as a case study based on our quantitative understanding of the in vivo chemistry. In an ongoing pretargeting project, we designed a trifunctional antibody (Ab) that concomitantly carried a biotin and a DNA analogue (hereafter termed MORF). The biotin and the MORF were fused into one structure prior to conjugation to the Ab for the concomitant attachment. Because it was known that avidin-bound Ab molecules leave the circulation rapidly, this design would theoretically allow complete clearance by avidin. The clearability of the trifunctional Ab was determined by calculating the blood MORF concentration ratio of avidin-treated Ab to non-avidin-treated Ab using mice injected with these compounds. In theory, any compromised clearability should be due to the presence of impurities. In vitro, we measured the biotinylated percentage of the Ab-reacting (MORF-biotin)⊃-NH2 modifier, by addition of streptavidin to the radiolabeled (MORF-biotin)⊃-NH2 samples and subsequent high-performance liquid chromatography (HPLC) analysis. On the basis of our previous quantitative understanding, we predicted that the clearability of the Ab would be equal to the biotinylation percentage measured via HPLC. We validated this prediction within a 3% difference. In addition to the high avidin-induced clearability of the trifunctional Ab (up to ∼95%) achieved by the design, we were able to predict the required quality of the (MORF-biotin)⊃-NH2 modifier for any given in vivo clearability. This approach may greatly reduce the steps and time currently required in pharmaceutical development in the process of synthesis, chemical analysis, in vitro cell study, and in vivo validation.

[1]  J. Virostko,et al.  A Feasible Approach to Evaluate the Relative Reactivity of NHS-Ester Activated Group with Primary Amine-Derivatized DNA Analogue and Non-Derivatized Impurity , 2015, Nucleosides, nucleotides & nucleic acids.

[2]  J. Virostko,et al.  Differentiation between temporary and real non-clearability of biotinylated IgG antibody by avidin in mice , 2014, Front. Pharmacol..

[3]  S. Larson,et al.  Evaluation of glycodendron and synthetically modified dextran clearing agents for multistep targeting of radioisotopes for molecular imaging and radioimmunotherapy. , 2014, Molecular pharmaceutics.

[4]  Xinrong Liu,et al.  Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted. , 2010, Cancer biotherapy & radiopharmaceuticals.

[5]  M. Rusckowski,et al.  An improved method for covalently conjugating morpholino oligomers to antitumor antibodies. , 2007, Bioconjugate chemistry.

[6]  M. Rusckowski,et al.  Radiolabeling of MAG3-morpholino oligomers with 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting. , 2006, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[7]  Xinrong Liu,et al.  Successful Radiotherapy of Tumor in Pretargeted Mice by 188Re-Radiolabeled Phosphorodiamidate Morpholino Oligomer, a Synthetic DNA Analogue , 2006, Clinical Cancer Research.

[8]  M. Rusckowski,et al.  Further investigations of morpholino pretargeting in mice—establishing quantitative relations in tumor , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  Jiang He,et al.  Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  Zhihong Zhu,et al.  Improving the labeling of S-acetyl NHS-MAG(3)-conjugated morpholino oligomers. , 2002, Bioconjugate chemistry.

[11]  M. Rusckowski,et al.  Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  P. Beaumier,et al.  Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Winnard,et al.  Preparation and use of NHS-MAG3 for technetium-99m labeling of DNA. , 1997, Nuclear medicine and biology.

[14]  S. Rosebrough.  Pharmacokinetics and biodistribution of radiolabeled avidin, streptavidin and biotin. , 1993, Nuclear medicine and biology.

[15]  A. Shnyra,et al.  Rapid blood clearance of biotinylated IgG after infusion of avidin. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.